SAGE - Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02 revenue of $1.5M misses by $0.27M
- Sage Therapeutics press release ( NASDAQ: SAGE ): Q2 GAAP EPS of -$2.13 beats by $0.02 .
- Revenue of $1.5M (-8.5% Y/Y) misses by $0.27M .
- Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022 were $1.5 billion compared to $1.6 billion at March 31, 2022
- Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022
-
Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD
-
Enrolling multiple Phase 2 studies across neuropsychiatry and neurology franchises, additional trials expected to initiate throughout 2022
- Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025
For further details see:
Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M